Multiple Sclerosis: Epidemiology Forecast to 2034

Multiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination, followed by axon damage and paralysis. MS symptoms include muscle weakness, weak reflexes, tremors, muscle spasms, prolonged double vision, slurred speech, and balance problems. MS can occur at any age, but commonly affects people aged 15-60 years. The diagnosis of MS depends upon patients’ symptoms, magnetic resonance imaging (MRI), and laboratory results, but it is mostly diagnosed in the late phases. Presently, MS is diagnosed by the widely used McDonald criteria, which is a combination of laboratory, clinical, and radiology reports of lesions at different times in different body areas. Currently, there is no cure for MS. However, treatment can help speed recovery from attacks, modify the course of the disease, and manage symptoms (Mayo Clinic, 2024).

In the 7MM, the diagnosed prevalent cases of MS are expected to increase from 1,612,928 cases in 2024 to 1,643,118 cases in 2034, at an annual growth rate (AGR) of 0.19%. In 2034, the US will have the highest number of diagnosed prevalent cases of MS in the 7MM, with 896,828 cases, whereas Japan will have the fewest cases, with 31,527 diagnosed prevalent cases. The analyst epidemiologists attribute the changes in the diagnosed prevalent cases to the underlying demographic changes in the respective markets.

Scope

• This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for MS in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of MS segmented by sex and age (pediatrics [ages 10-17 years], adults [ages ≥18 years], and all ages). The diagnosed prevalent cases of MS are additionally segmented by type (relapsing-remitting MS [RRMS], primary progressive MS [PPMS], and secondary progressive MS [SPMS]). The diagnosed prevalent cases of SPMS are further segmented as active and non-active. The forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the diagnosed prevalent cases of MS across these markets.

Reasons to Buy

The Multiple Sclerosis (MS) epidemiology series will allow you to:

• Develop business strategies by understanding the trends shaping and driving the global MS market.
• Quantify patient populations in the global MS market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for MS therapeutics in each of the markets covered.